US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CALIDI BIOTHERAPEUTICS INC

1.38

+0.04002.99%

Post-market: 1.29-0.0900-6.52%19:23 EDT

Volume:62.40K

Turnover:83.49K

Market Cap:3.57M

PE:-0.04

High:1.38

Open:1.34

Low:1.26

Close:1.34

52wk High:30.08

52wk Low:1.25

Shares:2.58M

Float Shares:2.56M

Volume Ratio:0.44

T/O Rate:2.44%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-33.3374

EPS(LYR):-95.1334

ROE:-672.22%

ROA:-134.79%

PB:1.14

PE(LYR):-0.01

Loading ...

Overview Company News Filings

Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY

Benzinga Earnings

Calidi Biotherapeutics Q2 FY26 Net Loss Narrows 26.32% to $4.2 Million; General and Administrative Expense Drops 48% to $1.6 Million

Calidi Biotherapeutics - Reports Q2 Net Loss of $4.20 Mln, or $2.94 Per Share

THOMSON REUTERS

Press Release: Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Calidi Biotherapeutics Effects 1-for-16 Reverse Stock Split

Calidi Biotherapeutics Targets Q1 2027 Clinic Entry for Cld-401 Cancer Program

Calidi Biotherapeutics Provides Mid-year Corporate Update and Future Key Value Drivers

THOMSON REUTERS

Calidi Biotherapeutics - Reduces G&a Expenses by $1 Mln from Q1 2025 to Q1 2026

THOMSON REUTERS

Calidi Biotherapeutics - Targets First Patient Dosing in Cld-401 Phase I Trial in Q1 2027

THOMSON REUTERS

Calidi Biotherapeutics Announces 1-for-16 Reverse Stock Split Effective July 31

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

THOMSON REUTERS

Calidi Biotherapeutics Grants VP Finance Inducement Option for 100,000 Shares at $0.15 Exercise Price

Calidi Biotherapeutics Director Corazon “corsee” Sanders Files Initial Beneficial Ownership Statement

Calidi Biotherapeutics Presents New Preclinical Data on Trop2-targeting Cld-501 at T-cell Engager Summit

Calidi Biotherapeutics appoints former Genentech, Celgene executive Corsee Sanders to board

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.d., to Board of Directors

THOMSON REUTERS

Calidi Biotherapeutics shareholders approve reverse stock split authorization

Calidi receives pre-IND regulatory feedback from FDA for CLD-401

Calidi Biotherapeutics targets early 2027 start for first-in-human CLD-401 trial after FDA pre-IND feedback

Calidi Biotherapeutics Receives Positive Pre-Ind Feedback From US FDA for Cld-401 Indicating Agreement on Its Current Development Strategy as It Advances Towards a First-in-Human Study

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/CLDI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CLDI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDI\",,,,,undefined,":{"symbol":"CLDI","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC","latestPrice":1.38,"timestamp":1787601600000,"preClose":1.34,"halted":0,"volume":62402,"hourTrading":{"tag":"盘后","latestPrice":1.29,"preClose":1.38,"latestTime":"19:23 EDT","volume":1063,"amount":1435.226,"timestamp":1787613797223,"change":-0.09,"changeRate":-0.065217,"amplitude":0.065217},"delay":0,"changeRate":0.029850746268656577,"floatShares":2555400,"shares":2584200,"eps":-33.337368,"marketStatus":"Not Yet Opened","change":0.04,"latestTime":"08-24 16:00:00 EDT","open":1.34,"high":1.38,"low":1.26,"amount":83492.3221902,"amplitude":0.089552,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-33.337368,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":0,"adr":0,"exchange":"AMEX","adjPreClose":1.34,"preHourTrading":{"tag":"盘前","latestPrice":1.35,"preClose":1.34,"latestTime":"09:11 EDT","volume":6507,"amount":8801.9154387,"timestamp":1787577073265,"change":0.01,"changeRate":0.007463,"amplitude":0.106269},"postHourTrading":{"tag":"盘后","latestPrice":1.29,"preClose":1.38,"latestTime":"19:23 EDT","volume":1063,"amount":1435.226,"timestamp":1787613797223,"change":-0.09,"changeRate":-0.065217,"amplitude":0.065217},"volumeRatio":0.438809},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDI\",,,,,undefined,":{"symbol":"CLDI","floatShares":2555400,"roa":"-134.79%","roe":"-672.22%","lyrEps":-95.133424,"volumeRatio":0.438809,"shares":2584200,"dividePrice":0,"high":1.38,"amplitude":0.089552,"preClose":1.34,"low":1.26,"week52Low":1.25,"pbRate":"1.14","week52High":30.08,"institutionHeld":0,"latestPrice":1.38,"eps":-33.337368,"divideRate":0,"volume":62402,"delay":0,"ttmEps":-33.337368,"open":1.34,"prevYearClose":18.72,"prevWeekClose":1.34,"prevMonthClose":1.64,"prevQuarterClose":2.72,"fiveDayClose":1.36,"twentyDayClose":1.752,"sixtyDayClose":3.04},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLDI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-31","symbol":"CLDI","defaultRemindTime":1785504600000,"type":"split","dateTimestamp":1785470400000,"forFactor":16,"toFactor":1,"ratio":16},{"market":"US","date":"2025-08-05","symbol":"CLDI","defaultRemindTime":1754400600000,"type":"split","dateTimestamp":1754366400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2024-07-15","symbol":"CLDI","defaultRemindTime":1721050200000,"type":"split","dateTimestamp":1721016000000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLDI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLDI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CLDI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CLDI","date":"2026-08-21","current":-0.041395,"percent":0.836676,"low":-6.02184,"twenty":-0.987327,"median":-0.481003,"eighty":-0.292874,"high":-0.088409,"avg":-0.723921,"sd":0.723661,"marketCap":3475369},"quantilePoints":[{"date":"2023-09-29","current":-3.638343,"twenty":-5.308141,"median":-4.713391,"eighty":-4.212002,"marketCap":116696199},{"date":"2023-10-06","current":-3.412521,"twenty":-4.832341,"median":-4.127586,"eighty":-3.638343,"marketCap":109453210},{"date":"2023-10-13","current":-3.406945,"twenty":-4.642021,"median":-3.525432,"eighty":-3.367913,"marketCap":109274365},{"date":"2023-10-20","current":-3.122569,"twenty":-4.220957,"median":-3.406945,"eighty":-3.283158,"marketCap":100153264},{"date":"2023-10-27","current":-2.788008,"twenty":-3.847474,"median":-3.379065,"eighty":-3.220707,"marketCap":89422557},{"date":"2023-11-03","current":-1.828933,"twenty":-3.642821,"median":-3.289849,"eighty":-2.58281,"marketCap":58661197},{"date":"2023-11-10","current":-2.263862,"twenty":-3.457685,"median":-3.122569,"eighty":-2.272784,"marketCap":72611116},{"date":"2023-11-17","current":-2.442295,"twenty":-3.40806,"median":-2.704368,"eighty":-2.257171,"marketCap":78334160},{"date":"2023-11-24","current":-2.219166,"twenty":-3.390217,"median":-2.436719,"eighty":-2.230406,"marketCap":63785485},{"date":"2023-12-01","current":-2.589027,"twenty":-3.358991,"median":-2.397687,"eighty":-2.219166,"marketCap":74416400},{"date":"2023-12-08","current":-2.860258,"twenty":-3.332227,"median":-2.436719,"eighty":-2.22591,"marketCap":82212403},{"date":"2023-12-15","current":-2.835601,"twenty":-3.283158,"median":-2.620727,"eighty":-2.230406,"marketCap":81503676},{"date":"2023-12-22","current":-2.220879,"twenty":-3.249702,"median":-2.454969,"eighty":-2.220879,"marketCap":63834719},{"date":"2023-12-29","current":-1.739688,"twenty":-3.220707,"median":-2.431143,"eighty":-2.219509,"marketCap":50003863},{"date":"2024-01-05","current":-1.752027,"twenty":-3.147103,"median":-2.407056,"eighty":-2.219166,"marketCap":50358500},{"date":"2024-01-12","current":-1.628644,"twenty":-3.080391,"median":-2.314664,"eighty":-2.158893,"marketCap":46812127},{"date":"2024-01-19","current":-1.492924,"twenty":-2.974346,"median":-2.305467,"eighty":-1.939518,"marketCap":42911116},{"date":"2024-01-26","current":-1.204827,"twenty":-2.880427,"median":-2.269438,"eighty":-1.766833,"marketCap":34630335},{"date":"2024-02-02","current":-0.987855,"twenty":-2.845464,"median":-2.230406,"eighty":-1.702674,"marketCap":28393922},{"date":"2024-02-09","current":-0.730889,"twenty":-2.828204,"median":-2.220879,"eighty":-1.569421,"marketCap":21007953},{"date":"2024-02-16","current":-0.617286,"twenty":-2.802114,"median":-2.220879,"eighty":-1.222224,"marketCap":17742652},{"date":"2024-02-23","current":-1.223953,"twenty":-2.75773,"median":-2.219166,"eighty":-1.201248,"marketCap":35180069},{"date":"2024-03-01","current":-0.737187,"twenty":-2.712314,"median":-2.219166,"eighty":-1.144986,"marketCap":21188964},{"date":"2024-03-08","current":-0.857685,"twenty":-2.707382,"median":-2.174646,"eighty":-1.007118,"marketCap":24652427},{"date":"2024-03-15","current":-0.752972,"twenty":-2.675328,"median":-2.00496,"eighty":-0.959654,"marketCap":21642662},{"date":"2024-03-22","current":-0.731293,"twenty":-2.63341,"median":-1.828933,"eighty":-0.834401,"marketCap":21365466},{"date":"2024-03-28","current":-0.690544,"twenty":-2.624956,"median":-1.776703,"eighty":-0.788933,"marketCap":20174941},{"date":"2024-04-05","current":-0.515506,"twenty":-2.614387,"median":-1.733519,"eighty":-0.77599,"marketCap":15061018},{"date":"2024-04-12","current":-0.778003,"twenty":-2.56475,"median":-1.702674,"eighty":-0.753894,"marketCap":22730126},{"date":"2024-04-19","current":-0.277851,"twenty":-2.462573,"median":-1.585461,"eighty":-0.73922,"marketCap":8117685},{"date":"2024-04-26","current":-0.277851,"twenty":-2.440065,"median":-1.494131,"eighty":-0.729834,"marketCap":8117685},{"date":"2024-05-03","current":-0.33683,"twenty":-2.428199,"median":-1.326872,"eighty":-0.713833,"marketCap":9840816},{"date":"2024-05-10","current":-0.388779,"twenty":-2.412677,"median":-1.223953,"eighty":-0.694949,"marketCap":11358553},{"date":"2024-05-17","current":-0.395215,"twenty":-2.384304,"median":-1.201804,"eighty":-0.67322,"marketCap":11848146},{"date":"2024-05-24","current":-0.389826,"twenty":-2.327552,"median":-1.110439,"eighty":-0.59822,"marketCap":11686581},{"date":"2024-05-31","current":-0.489936,"twenty":-2.314664,"median":-1.049596,"eighty":-0.481812,"marketCap":14687785},{"date":"2024-06-07","current":-0.316825,"twenty":-2.30847,"median":-0.987793,"eighty":-0.405177,"marketCap":9498101},{"date":"2024-06-14","current":-0.471065,"twenty":-2.306068,"median":-0.973968,"eighty":-0.411637,"marketCap":14122049},{"date":"2024-06-21","current":-0.417535,"twenty":-2.287195,"median":-0.942383,"eighty":-0.415168,"marketCap":12517271},{"date":"2024-06-28","current":-0.442801,"twenty":-2.275014,"median":-0.891807,"eighty":-0.416445,"marketCap":13274726},{"date":"2024-07-05","current":-0.415179,"twenty":-2.275014,"median":-0.841776,"eighty":-0.414794,"marketCap":12446661},{"date":"2024-07-12","current":-0.324606,"twenty":-2.266092,"median":-0.802632,"eighty":-0.404243,"marketCap":9731376},{"date":"2024-07-15","current":-0.338952,"twenty":-2.263862,"median":-0.798467,"eighty":-0.400509,"marketCap":10161455},{"date":"2024-08-02","current":-0.357581,"twenty":-2.257171,"median":-0.794302,"eighty":-0.396487,"marketCap":10719918},{"date":"2024-08-09","current":-0.398883,"twenty":-2.230406,"median":-0.779498,"eighty":-0.390904,"marketCap":11958114},{"date":"2024-08-16","current":-0.480755,"twenty":-2.230406,"median":-0.778003,"eighty":-0.392451,"marketCap":11175142},{"date":"2024-08-23","current":-0.500804,"twenty":-2.228501,"median":-0.759804,"eighty":-0.395268,"marketCap":11641180},{"date":"2024-08-30","current":-0.382558,"twenty":-2.220879,"median":-0.750634,"eighty":-0.391354,"marketCap":8892568},{"date":"2024-09-06","current":-0.39647,"twenty":-2.220879,"median":-0.737187,"eighty":-0.391253,"marketCap":9215934},{"date":"2024-09-13","current":-0.403425,"twenty":-2.220879,"median":-0.730361,"eighty":-0.39176,"marketCap":9377617},{"date":"2024-09-20","current":-0.384297,"twenty":-2.220879,"median":-0.726938,"eighty":-0.391253,"marketCap":8932989},{"date":"2024-09-27","current":-0.420814,"twenty":-2.219166,"median":-0.713995,"eighty":-0.389826,"marketCap":9781825},{"date":"2024-10-04","current":-0.375603,"twenty":-2.219166,"median":-0.705506,"eighty":-0.388779,"marketCap":8730885},{"date":"2024-10-11","current":-0.484689,"twenty":-2.219166,"median":-0.691943,"eighty":-0.386036,"marketCap":11266594},{"date":"2024-10-18","current":-0.559329,"twenty":-2.219166,"median":-0.675446,"eighty":-0.386036,"marketCap":13001597},{"date":"2024-10-25","current":-0.336452,"twenty":-2.219166,"median":-0.638834,"eighty":-0.386036,"marketCap":7820838},{"date":"2024-10-31","current":-0.530552,"twenty":-2.18355,"median":-0.601504,"eighty":-0.386036,"marketCap":12332679},{"date":"2024-11-08","current":-0.740861,"twenty":-2.174646,"median":-0.630927,"eighty":-0.38823,"marketCap":17221309},{"date":"2024-11-15","current":-0.849939,"twenty":-2.111632,"median":-0.664773,"eighty":-0.389367,"marketCap":22332149},{"date":"2024-11-22","current":-1.580558,"twenty":-2.067561,"median":-0.675446,"eighty":-0.389764,"marketCap":41529165},{"date":"2024-11-29","current":-1.558504,"twenty":-1.993856,"median":-0.690544,"eighty":-0.390682,"marketCap":40949688},{"date":"2024-12-06","current":-1.477638,"twenty":-1.934558,"median":-0.69736,"eighty":-0.391557,"marketCap":38824940},{"date":"2024-12-13","current":-1.374718,"twenty":-1.867215,"median":-0.712804,"eighty":-0.392499,"marketCap":36120716},{"date":"2024-12-20","current":-1.065958,"twenty":-1.812401,"median":-0.717637,"eighty":-0.394326,"marketCap":28008041},{"date":"2024-12-27","current":-1.088012,"twenty":-1.791509,"median":-0.728386,"eighty":-0.395322,"marketCap":28587518},{"date":"2025-01-03","current":-0.867469,"twenty":-1.774231,"median":-0.730361,"eighty":-0.39568,"marketCap":22792751},{"date":"2025-01-10","current":-0.992443,"twenty":-1.764344,"median":-0.73424,"eighty":-0.39647,"marketCap":26076452},{"date":"2025-01-17","current":-0.658321,"twenty":-1.752027,"median":-0.729834,"eighty":-0.39647,"marketCap":17297380},{"date":"2025-01-24","current":-0.559444,"twenty":-1.742156,"median":-0.726938,"eighty":-0.39647,"marketCap":14699393},{"date":"2025-01-31","current":-0.459906,"twenty":-1.730007,"median":-0.713995,"eighty":-0.3984,"marketCap":12084021},{"date":"2025-02-07","current":-1.088012,"twenty":-1.727397,"median":-0.721011,"eighty":-0.399734,"marketCap":28587518},{"date":"2025-02-14","current":-0.992443,"twenty":-1.707609,"median":-0.729834,"eighty":-0.399947,"marketCap":26076452},{"date":"2025-02-21","current":-0.926281,"twenty":-1.702674,"median":-0.731091,"eighty":-0.399947,"marketCap":24338022},{"date":"2025-02-28","current":-0.612521,"twenty":-1.691156,"median":-0.729834,"eighty":-0.399947,"marketCap":16094000},{"date":"2025-03-07","current":-0.624578,"twenty":-1.650578,"median":-0.723974,"eighty":-0.400284,"marketCap":16410780},{"date":"2025-03-14","current":-0.571942,"twenty":-1.617436,"median":-0.713824,"eighty":-0.401215,"marketCap":15027763},{"date":"2025-03-21","current":-0.580763,"twenty":-1.605553,"median":-0.709155,"eighty":-0.402729,"marketCap":15259553},{"date":"2025-03-28","current":-0.511219,"twenty":-1.596023,"median":-0.693342,"eighty":-0.403425,"marketCap":13432270},{"date":"2025-04-04","current":-0.459715,"twenty":-1.584987,"median":-0.688902,"eighty":-0.403425,"marketCap":10179474},{"date":"2025-04-11","current":-0.669232,"twenty":-1.579798,"median":-0.693063,"eighty":-0.404476,"marketCap":14818796},{"date":"2025-04-17","current":-0.762727,"twenty":-1.576858,"median":-0.698757,"eighty":-0.405589,"marketCap":16889069},{"date":"2025-04-25","current":-0.815708,"twenty":-1.567326,"median":-0.703771,"eighty":-0.407877,"marketCap":18062224},{"date":"2025-05-02","current":-0.791432,"twenty":-1.558504,"median":-0.712804,"eighty":-0.410381,"marketCap":17524679},{"date":"2025-05-09","current":-0.680714,"twenty":-1.556948,"median":-0.713079,"eighty":-0.410531,"marketCap":15073040},{"date":"2025-05-16","current":-0.757287,"twenty":-1.55323,"median":-0.713725,"eighty":-0.411705,"marketCap":15073040},{"date":"2025-05-23","current":-0.755462,"twenty":-1.548212,"median":-0.715532,"eighty":-0.413178,"marketCap":15036720},{"date":"2025-05-30","current":-0.635937,"twenty":-1.533867,"median":-0.715532,"eighty":-0.413252,"marketCap":12657684},{"date":"2025-06-06","current":-0.601845,"twenty":-1.49389,"median":-0.713725,"eighty":-0.413637,"marketCap":11979114},{"date":"2025-06-13","current":-0.579566,"twenty":-1.491337,"median":-0.71226,"eighty":-0.415179,"marketCap":11535691},{"date":"2025-06-20","current":-0.49788,"twenty":-1.484989,"median":-0.706232,"eighty":-0.415179,"marketCap":9909811},{"date":"2025-06-27","current":-0.38649,"twenty":-1.477638,"median":-0.701377,"eighty":-0.415179,"marketCap":7692700},{"date":"2025-07-03","current":-0.414844,"twenty":-1.438928,"median":-0.693342,"eighty":-0.413227,"marketCap":8257056},{"date":"2025-07-11","current":-1.684355,"twenty":-1.438928,"median":-0.693202,"eighty":-0.413227,"marketCap":33525394},{"date":"2025-07-18","current":-1.123887,"twenty":-1.426793,"median":-0.701377,"eighty":-0.413252,"marketCap":22369845},{"date":"2025-07-25","current":-1.408554,"twenty":-1.420297,"median":-0.706232,"eighty":-0.414526,"marketCap":28035855},{"date":"2025-08-01","current":-1.087209,"twenty":-1.418827,"median":-0.712804,"eighty":-0.414844,"marketCap":21639801},{"date":"2025-08-08","current":-0.875894,"twenty":-1.410609,"median":-0.713774,"eighty":-0.415112,"marketCap":17433803},{"date":"2025-08-15","current":-0.869891,"twenty":-1.399128,"median":-0.7168,"eighty":-0.415179,"marketCap":17269086},{"date":"2025-08-22","current":-0.293416,"twenty":-1.396772,"median":-0.714044,"eighty":-0.415112,"marketCap":5824890},{"date":"2025-08-29","current":-0.333904,"twenty":-1.384858,"median":-0.713355,"eighty":-0.413227,"marketCap":6628654},{"date":"2025-09-05","current":-0.306566,"twenty":-1.377583,"median":-0.711715,"eighty":-0.410381,"marketCap":6085957},{"date":"2025-09-12","current":-0.318282,"twenty":-1.365896,"median":-0.706232,"eighty":-0.404476,"marketCap":6318541},{"date":"2025-09-19","current":-0.308519,"twenty":-1.353336,"median":-0.701377,"eighty":-0.401215,"marketCap":6124721},{"date":"2025-09-26","current":-0.294091,"twenty":-1.33881,"median":-0.693202,"eighty":-0.399947,"marketCap":5838288},{"date":"2025-10-03","current":-0.316401,"twenty":-1.31392,"median":-0.68726,"eighty":-0.39647,"marketCap":6281193},{"date":"2025-10-10","current":-0.322486,"twenty":-1.292622,"median":-0.675448,"eighty":-0.392499,"marketCap":6401985},{"date":"2025-10-17","current":-0.326542,"twenty":-1.284205,"median":-0.672663,"eighty":-0.38922,"marketCap":6482513},{"date":"2025-10-24","current":-0.308288,"twenty":-1.276188,"median":-0.670475,"eighty":-0.387098,"marketCap":6120137},{"date":"2025-10-31","current":-0.320457,"twenty":-1.271824,"median":-0.660381,"eighty":-0.385104,"marketCap":6361721},{"date":"2025-11-07","current":-0.336683,"twenty":-1.27075,"median":-0.656627,"eighty":-0.382558,"marketCap":6683833},{"date":"2025-11-14","current":-0.308288,"twenty":-1.248314,"median":-0.646559,"eighty":-0.37908,"marketCap":6120137},{"date":"2025-11-21","current":-0.506264,"twenty":-1.227901,"median":-0.642788,"eighty":-0.378051,"marketCap":10098454},{"date":"2025-11-28","current":-0.553956,"twenty":-1.216303,"median":-0.637388,"eighty":-0.378665,"marketCap":11049758},{"date":"2025-12-05","current":-0.564962,"twenty":-1.204728,"median":-0.625828,"eighty":-0.37908,"marketCap":11269290},{"date":"2025-12-12","current":-0.539282,"twenty":-1.202359,"median":-0.624725,"eighty":-0.379407,"marketCap":10757049},{"date":"2025-12-19","current":-0.480584,"twenty":-1.198139,"median":-0.617286,"eighty":-0.380537,"marketCap":9586214},{"date":"2025-12-26","current":-0.473247,"twenty":-1.193728,"median":-0.613551,"eighty":-0.381709,"marketCap":9439860},{"date":"2026-01-02","current":-0.429224,"twenty":-1.181411,"median":-0.606978,"eighty":-0.382558,"marketCap":8561733},{"date":"2026-01-09","current":-0.425556,"twenty":-1.152719,"median":-0.601338,"eighty":-0.382558,"marketCap":8488556},{"date":"2026-01-16","current":-0.381533,"twenty":-1.123887,"median":-0.596031,"eighty":-0.382558,"marketCap":7610429},{"date":"2026-01-23","current":-0.381533,"twenty":-1.113129,"median":-0.591212,"eighty":-0.381526,"marketCap":7610429},{"date":"2026-01-30","current":-0.385201,"twenty":-1.10426,"median":-0.583111,"eighty":-0.37908,"marketCap":7683607},{"date":"2026-02-06","current":-0.308931,"twenty":-1.10252,"median":-0.580763,"eighty":-0.3778,"marketCap":6162252},{"date":"2026-02-13","current":-0.278812,"twenty":-1.090904,"median":-0.575754,"eighty":-0.374195,"marketCap":5561467},{"date":"2026-02-20","current":-0.26843,"twenty":-1.088012,"median":-0.566497,"eighty":-0.373137,"marketCap":5354376},{"date":"2026-02-27","current":-0.310362,"twenty":-1.08753,"median":-0.56401,"eighty":-0.369399,"marketCap":6190791},{"date":"2026-03-06","current":-0.282371,"twenty":-1.0848,"median":-0.559387,"eighty":-0.36189,"marketCap":5632449},{"date":"2026-03-13","current":-0.174784,"twenty":-1.08267,"median":-0.557624,"eighty":-0.357961,"marketCap":3486416},{"date":"2026-03-20","current":-0.158448,"twenty":-1.081325,"median":-0.553956,"eighty":-0.344782,"marketCap":3160553},{"date":"2026-03-27","current":-0.148693,"twenty":-1.078568,"median":-0.550287,"eighty":-0.336771,"marketCap":2965985},{"date":"2026-04-02","current":-0.134617,"twenty":-1.073376,"median":-0.545256,"eighty":-0.334923,"marketCap":2679692},{"date":"2026-04-10","current":-0.142941,"twenty":-1.067403,"median":-0.543606,"eighty":-0.331139,"marketCap":2845378},{"date":"2026-04-17","current":-0.153817,"twenty":-1.066944,"median":-0.540074,"eighty":-0.327107,"marketCap":3061874},{"date":"2026-04-24","current":-0.122077,"twenty":-1.066514,"median":-0.537448,"eighty":-0.325201,"marketCap":2430059},{"date":"2026-05-01","current":-0.13151,"twenty":-1.065958,"median":-0.535582,"eighty":-0.324514,"marketCap":2617836},{"date":"2026-05-08","current":-0.120135,"twenty":-1.065958,"median":-0.532096,"eighty":-0.32282,"marketCap":2391399},{"date":"2026-05-15","current":-0.14671,"twenty":-1.063017,"median":-0.526887,"eighty":-0.322188,"marketCap":2920400},{"date":"2026-05-22","current":-0.155096,"twenty":-1.055002,"median":-0.522094,"eighty":-0.320457,"marketCap":2951158},{"date":"2026-05-29","current":-0.15356,"twenty":-1.046879,"median":-0.517003,"eighty":-0.317116,"marketCap":2921938},{"date":"2026-06-05","current":-0.140629,"twenty":-1.031095,"median":-0.513601,"eighty":-0.31633,"marketCap":2675880},{"date":"2026-06-12","current":-0.136588,"twenty":-1.010842,"median":-0.511292,"eighty":-0.314373,"marketCap":2598987},{"date":"2026-06-18","current":-0.122848,"twenty":-1.008527,"median":-0.506543,"eighty":-0.312424,"marketCap":2337551},{"date":"2026-06-26","current":-0.153214,"twenty":-1.002903,"median":-0.500804,"eighty":-0.312345,"marketCap":2915351},{"date":"2026-07-02","current":-0.161601,"twenty":-1.000417,"median":-0.498226,"eighty":-0.310311,"marketCap":3074936},{"date":"2026-07-10","current":-0.153111,"twenty":-0.999795,"median":-0.493476,"eighty":-0.308473,"marketCap":2913405},{"date":"2026-07-17","current":-0.118234,"twenty":-0.999795,"median":-0.489941,"eighty":-0.308288,"marketCap":2249763},{"date":"2026-07-24","current":-0.107393,"twenty":-0.993913,"median":-0.489211,"eighty":-0.304549,"marketCap":2043470},{"date":"2026-07-31","current":-0.095426,"twenty":-0.992443,"median":-0.486947,"eighty":-0.304232,"marketCap":1815768},{"date":"2026-08-07","current":-0.114424,"twenty":-0.98969,"median":-0.484689,"eighty":-0.301652,"marketCap":2177268},{"date":"2026-08-14","current":-0.098443,"twenty":-0.987781,"median":-0.481792,"eighty":-0.298405,"marketCap":1873180},{"date":"2026-08-21","current":-0.198899,"twenty":-0.987327,"median":-0.481003,"eighty":-0.292874,"marketCap":3475369}],"updateTime":1787613330651},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLDI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659878160","title":"Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2659878160","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659878160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:41","pubTimestamp":1786653680,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.94) per share. This is a 47.74 percent decrease over losses of $(1.99) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61195429/calidi-biotherapeutics-q2-eps-2-94-down-1-99-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167081","title":"Calidi Biotherapeutics Q2 FY26 Net Loss Narrows 26.32% to $4.2 Million; General and Administrative Expense Drops 48% to $1.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167081","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167081?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:37","pubTimestamp":1786653450,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Q2 FY26 net loss narrows 26.32% to $4.2 million; general and administrative expense drops 48% to $1.6 millionCalidi Biotherapeutics posted a net loss attributable to common stoc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL7bqM0w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BKPKM429.USD","BK4112","BCDF","IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD","SG9999014039.USD","LU0314104364.USD","SG9999014013.SGD","BK4139","SG9999014021.USD","SG9999014005.SGD","CLDI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659198958","title":"Calidi Biotherapeutics - Reports Q2 Net Loss of $4.20 Mln, or $2.94 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2659198958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659198958?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:30","pubTimestamp":1786653000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA5PG1XW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167281","title":"Press Release: Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167281","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167281?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:30","pubTimestamp":1786653000,"startTime":"0","endTime":"0","summary":"CMC and non-clinical programs, and the FDA provided feedback on the. overall design for the proposed first-in-human clinical study. This. pre-IND  interaction builds upon the engagement and alignment. achieved through early scientific advice as part of a Type D interaction. -- Presented preclinical data at the 2026 American Society of Clinical. Oncology  Annual Meeting on CLD-501, the lead compound from. Calidi's in situ TCE approach. CLD-501 is a systemically delivered. virotherapy designed to selectively target tumors and simultaneously. enable the high-level in situ expression of a TROP-2 TCE and IL-15. superagonist . The Company also presented preclinical data on. CLD-401, its lead program. CLD-401 is a systemically delivered. virotherapy designed to selectively target tumors and enable high-level. expression of IL-15 SA, a known T- and NK-cell activator, driving. profound immune changes in the tumor microenvironment, including the. recruitment and activation of NK, NK-T, and gamma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539110","title":"Calidi Biotherapeutics Effects 1-for-16 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539110","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656539110?lang=en_us&edition=fundamental","pubTime":"2026-08-01 05:00","pubTimestamp":1785531659,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics effects 1-for-16 reverse stock splitCalidi Biotherapeutics executed a 1-for-16 reverse stock split of its common stock, effective July 30, 2026.Shares began trading on a split-a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL7tz7Qb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654120017","title":"Calidi Biotherapeutics Targets Q1 2027 Clinic Entry for Cld-401 Cancer Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2654120017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654120017?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:06","pubTimestamp":1785153969,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics targets Q1 2027 clinic entry for CLD-401 cancer programCalidi Biotherapeutics presented new preclinical data on its CLD-401 cancer program at the AACR Drug Discovery and Develop","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDLbTSsHP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","SG9999014039.USD","SG9999014021.USD","BCDF","SG9999014005.SGD","BK4585","LU2095319765.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4139","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","CLDI","LU0314104364.USD","NDAQ","IE00BKPKM429.USD","LU2210149790.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653914272","title":"Calidi Biotherapeutics Provides Mid-year Corporate Update and Future Key Value Drivers","url":"https://stock-news.laohu8.com/highlight/detail?id=2653914272","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653914272?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:00","pubTimestamp":1784635204,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nTUACH1XNK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653272239","title":"Calidi Biotherapeutics - Reduces G&a Expenses by $1 Mln from Q1 2025 to Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653272239","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653272239?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:00","pubTimestamp":1784635204,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nTUACH1XNK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653272236","title":"Calidi Biotherapeutics - Targets First Patient Dosing in Cld-401 Phase I Trial in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2653272236","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653272236?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:00","pubTimestamp":1784635204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nTUACH1XNK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653245231","title":"Calidi Biotherapeutics Announces 1-for-16 Reverse Stock Split Effective July 31","url":"https://stock-news.laohu8.com/highlight/detail?id=2653245231","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653245231?lang=en_us&edition=fundamental","pubTime":"2026-07-21 04:30","pubTimestamp":1784579415,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics announces 1-for-16 reverse stock split effective July 31Calidi Biotherapeutics will implement a 1-for-16 reverse stock split of its common stock.Shares are expected to begin tra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL4XzQsX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","LU2210149790.SGD","BK4585","BK4139","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","BCDF","CLDI","IE00BN0W2W23.USD","SG9999014039.USD","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653454012","title":"Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653454012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653454012?lang=en_us&edition=fundamental","pubTime":"2026-07-21 04:30","pubTimestamp":1784579400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUA4PBN1T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650915927","title":"Calidi Biotherapeutics Grants VP Finance Inducement Option for 100,000 Shares at $0.15 Exercise Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2650915927","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650915927?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:07","pubTimestamp":1783541258,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics grants VP Finance inducement option for 100,000 shares at $0.15 exercise priceCalidi Biotherapeutics granted VP Finance, Controller Sandra Gurrola a non-qualified stock option c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL4mv8YY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2W23.USD","LU2210149790.SGD","CLDI","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","IE00BN0W2T93.GBP","LU2095319765.USD","BK4112","NDAQ","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","SG9999014021.USD","BCDF","LU0314104364.USD","SG9999014039.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647330738","title":"Calidi Biotherapeutics Director Corazon “corsee” Sanders Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2647330738","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647330738?lang=en_us&edition=fundamental","pubTime":"2026-06-30 05:13","pubTimestamp":1782767618,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics director Corazon “Corsee” Sanders files initial beneficial ownership statementCalidi Biotherapeutics director Corazon (Corsee) D. Sanders filed an initial Form 3 on June 29 tied","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL8W169R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645904638","title":"Calidi Biotherapeutics Presents New Preclinical Data on Trop2-targeting Cld-501 at T-cell Engager Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2645904638","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645904638?lang=en_us&edition=fundamental","pubTime":"2026-06-24 20:00","pubTimestamp":1782302423,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics presents new preclinical data on TROP2-targeting CLD-501 at T-cell engager summitCalidi Biotherapeutics presented new preclinical data on June 24, 2026 for CLD-501, a tumor-targ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL8JF4dh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014039.USD","BK4585","LU2210149790.SGD","BK4139","IE00BN0W2V16.EUR","BK4112","BK4588","CLDI","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2095319765.USD","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645083547","title":"Calidi Biotherapeutics appoints former Genentech, Celgene executive Corsee Sanders to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2645083547","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645083547?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:01","pubTimestamp":1782216102,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics appointed Corsee Sanders, Ph.D., to its board as an independent director, effective June 17, 2026.Sanders previously served as a strategic advisor to Celgene’s CMO following its Juno acquisition, where she was EVP of Development Operations.She also advised Bristol Myers Squibb on integrating Juno’s CAR-T development organization into Celgene and BMS.Earlier, Sanders spent 23 years at Genentech/Roche, including six years as SVP, global head of clinical operations and industry collaboration.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL74nQCR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BJT1NW94.SGD","LU2210149790.SGD","LU1983299246.USD","LU1032466523.USD","LU1883839398.USD","LU2242652126.USD","SG9999014021.USD","LU1718418525.SGD","IE00BSNM7G36.USD","BK4007","LU2242646821.SGD","LU0061475181.USD","LU1430594728.SGD","LU0306806265.USD","LU1323610961.USD","NDAQ","IE00BJJMRZ35.SGD","IE00BGHQF748.EUR","LU0868494617.USD","LU1670711040.USD","BK4585","LU2095319765.USD","LU0432979614.USD","IE00B3QW5Z07.USD","BK4139","LU1670711123.USD","LU0237698245.USD","BMY","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0267386448.USD","LU0314104364.USD","LU0321505868.SGD","LU1093756325.SGD","LU1571399168.USD","LU1868836591.USD","BK4112","LU1868837300.USD","LU0225771236.USD","LU0306807586.USD","LU1989771016.USD","BK4534","LU1670710588.SGD","IE00BN0W2T93.GBP","CLDI","LU0985481810.HKD","IE00BN0W2V16.EUR","IE00BFXG1179.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835128","title":"Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.d., to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835128","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835128?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:00","pubTimestamp":1782216005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA1RCJZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","RARE","CLDI","LEGN","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644039269","title":"Calidi Biotherapeutics shareholders approve reverse stock split authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=2644039269","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644039269?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:01","pubTimestamp":1781816494,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics held its annual stockholder meeting on June 12, 2026.Stockholders backed a charter amendment authorizing a reverse stock split, subject to board discretion, at a ratio between 1-for-2 and 1-for-16.Stockholders authorized an increase in shares available under the 2023 equity incentive plan to 1,950,000 from 282,815.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL7XZyLl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643757846","title":"Calidi receives pre-IND regulatory feedback from FDA for CLD-401","url":"https://stock-news.laohu8.com/highlight/detail?id=2643757846","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643757846?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:39","pubTimestamp":1781613560,"startTime":"0","endTime":"0","summary":"Calidi (CLDI) announced that it has received pre-IND regulatory feedback from the FDA providing alignment and clarity on Calidi’s IND-enabling prec...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/calidi-receives-pre-ind-regulatory-feedback-from-fda-for-cld-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/calidi-receives-pre-ind-regulatory-feedback-from-fda-for-cld-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IND","BK4139","CLDI","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643754784","title":"Calidi Biotherapeutics targets early 2027 start for first-in-human CLD-401 trial after FDA pre-IND feedback","url":"https://stock-news.laohu8.com/highlight/detail?id=2643754784","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643754784?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:03","pubTimestamp":1781611407,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics received positive pre-IND feedback from the US FDA for CLD-401, supporting its current development and clinical strategy.No clinical results were presented; the update centers on regulatory alignment ahead of a first-in-human Phase 1 study planned for early 2027.Management framed the feedback as reducing regulatory uncertainty, keeping the program on track toward an IND submission targeted by year-end 2026.CLD-401 is positioned as a potential oncolytic virus therapy candidate intended to drive early clinical validation of Calidi’s RedTail platform.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL8VJkMF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","CLDI","IE00BKPKM429.USD","BK4588","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4112","IE00BN0W2W23.USD","SG9999014039.USD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643544387","title":"Calidi Biotherapeutics Receives Positive Pre-Ind Feedback From US FDA for Cld-401 Indicating Agreement on Its Current Development Strategy as It Advances Towards a First-in-Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643544387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643544387?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:00","pubTimestamp":1781611200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA6C20TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":62,"code":"91000000","status":"200"}]}}